Business
AGM & EGM Statement
AGM & EGM Statement.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n25 July 2011\n\n Scancell Holdings Plc \n\n Result of AGM and General Meeting \n\nScancell Holdings plc, (`Scancell' or the `Company') the developer of\ntherapeutic cancer vaccines, is pleased to announce the following:\n\nResult of Annual General Meeting\n\nAll resolutions proposed at the Annual General Meeting held earlier today were\nduly passed.\n\nResult of General Meeting\n\nAll resolutions proposed at the General Meeting held earlier today were duly\npassed. Following the passing of the resolutions the Company can now proceed\nwith the subdivision of each Existing Ordinary Share of 1p into 10 new Ordinary\nShares of 0.1p each (the \"Subdivision\") and the placing to raise £1.73 million,\nbefore costs, by means of the issue of 34,575,410 new Ordinary Shares at 5\npence per share (the \"Placing\") to fund the working capital of the Company.\n\nThe Company has made an application to the London Stock Exchange and it is\nexpected that Admission of the new Ordinary Shares and the Placing Shares will\ntake place on 26 July 2011.\n\nFollowing Admission, the Company will have a single class of shares being\nOrdinary Shares of 0.1 pence each and there will be 194,093,310 Ordinary Shares\nin issue, each carrying one vote per Ordinary Share. The Company does not hold\nany Ordinary Shares in treasury. The total number of voting rights in the\nCompany's Ordinary Shares will be 194,093,310 and this number may be used by\nshareholders as the denominator in calculations to determine if they are\nrequired to notify their interest in, or a change to their interest in, the\nshare capital of the Company under the Financial Services Authority's\nDisclosure and Transparency Rules.\n\nDefinitions in this announcement are consistent with those set out in the\nCircular issued to shareholders of the Company and dated 30 June 2011, a copy\nof which is available on the Company's website.\n\nEnquiries:\n\nScancell Holdings Plc + 44 (0)207 245 1100 \n \nProfessor Lindy Durrant/Dr Richard Goodfellow \n \nHansard Communications + 44 (0)207 245 1100 \n \nAdam Reynolds/Guy McDougall \n \nZeus Capital - Nominated Adviser + 44 (0)161 831 1512 \n \nRoss Andrews/Tom Rowley \n \nXCAP Securities Plc - Broker +44 (0) 207 101 7070 \n \nJohn Belliss/Parimal Kumar \n\n\n \n ","length":3313,"tagName":"div"}]